SCHEMBL24030205

SCHEMBL24030205

CC(C)(C)OC(=O)N1CCCC(Cn2c(Cl)cc(=O)[nH]c2=O)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FEN1 P39748 1/20 0.49
▸ HTR6 P50406 4/20 0.47
▸ CYP2C9 P11712 1/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ BACE1 P56817 2/20 0.43
▸ CTSD P07339 1/20 0.43
▸ SCN9A Q15858 1/20 0.41
▸ CHEK2 O96017 1/20 0.41
▸ ACKR3 P25106 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GLS O94925 1/20 0.40
▸ BCHE P06276 2/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ PARP2 Q9UGN5 1/20 0.40
▸ FNTA P49354 1/20 0.40
▸ FNTB P49356 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24030429 1.00 FEN1 (0.49) FEN1HTR6CYP2C9MAPTKDM4E
SCHEMBL24030203 1.00 FEN1 (0.49) FEN1HTR6CYP2C9MAPTKDM4E
SCHEMBL24030443 0.82 KDM4E (0.43) HTR6MAPTKDM4ETHRBPARP1
SCHEMBL24030211 0.82 KDM4E (0.43) HTR6MAPTKDM4ETHRBPARP1
SCHEMBL24030459 0.82 KDM4E (0.43) HTR6MAPTKDM4ETHRBPARP1
SCHEMBL30025877 0.78 PDE8B (0.44) MAPTKDM4ETHRBCHEK2MEN1
SCHEMBL18645206 0.74 HTR6 (0.53) FEN1HTR6CYP2C9BACE1CTSD
SCHEMBL4975994 0.73 MEN1 (0.56) FEN1CYP2C9MAPTBACE1CTSD
SCHEMBL3489029 0.72 MEN1 (0.54) FEN1HTR6CYP2C9MAPTBACE1
SCHEMBL19924652 0.72 BACE1 (0.47) FEN1HTR6CYP2C9MAPTBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630551-B2 Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof NEUSCO BIOTECH LIMITED (CN) 2026-05-19 — — US disclosed
US-20230212168-A1 ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF NEUSCO BIOTECH LIMITED (CN) 2023-07-06 — — US disclosed
US-20230212168-A1 ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF NEUSCO BIOTECH LIMITED (CN) 2023-07-06 — — US disclosed
US-20230212168-A1 ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF NEUSCO BIOTECH LIMITED (CN) 2023-07-06 — — US disclosed
EP-4151638-A1 BRIDGED CYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING SAME AND USE THEREOF Neusco Biotech Limited (CN) 2023-03-22 — — EP disclosed
WO-2021228159-A1 BRIDGED CYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING SAME AND USE THEREOF 上海纽思克生物科技有限公司 2021-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212168-A1 ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF PLA2G1B, PLA2G5, PLA2G4B FEN1 1048/4885HTR6 2810/4885CYP2C9 3252/4885
US-12630551-B2 Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof LPAR1, PLA2R1, LPAR2 FEN1 1236/4885HTR6 854/4885CYP2C9 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback